Argentina reports its first cases of the Lineage B.1.617 variant in two people who travelled from Paris, as well as its first case of the Lineage B.1.351 variant in a person who travelled from Spain. 2021-05-10
The World Health Organization classifies the Lineage B.1.617 variant as a "Variant of Concern", becoming the fourth variant to be designated as being of global concern after the B.1.1.7, B.1.351, and P.1 variants. 2021-05-10
Malta reports four more cases of the 501.V2 variant that originated in South Africa. 2021-04-23
Moderna says its vaccine is 90% effective against COVID-19, and 95% effective against severe disease for six months after the second dose. It also says its vaccine is effective against the 501.V2 variant from South Africa. 2021-04-13
Pfizer announces a revised efficacy rating of 91.3% for its vaccine candidate, down from its original rating of 95%, and affirms that protection afforded by the vaccine lasts for at least six months. Pfizer also announces that the vaccine appeared to provide protection against the 501.V2 variant in 100% of cases during its South African trial run. 2021-04-1
Wisconsin confirms their first cases of the Lineage P.1 and 501.V2 variant of SARS-CoV-2. 2021-03-26
Washington, D.C. confirms its first cases of the 501.V2 variant from South Africa and the UK variant of SARS-CoV-2. 2021-02-11
South Africa suspends its rollout of the Oxford-AstraZenenca vaccine after research finds that the vaccine is less effective against the 501.V2 variant discovered in the country. 2021-02-7
Portugal also reports their first case of the 501.V2 variant that originated in South Africa. They do not indicate whether the individual travelled. 2021-01-22